Search filters
Filters
Clear All

Phase

  • 1
  • 1
  • 1
  • 1

Found 1 Anger trials

A listing of Anger medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 17518: A Phase 1 First-in-Human Open-Label Dose Escalation Study of MGD013 A Bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

99 years or below
All genders
Phase 1
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
Learn More